Speaker Profile
Other, CEO & Founder, Alethios
Biography
Zeenia Framroze is a researcher and entrepreneur who founded Alethios to lower the barriers to evidence generation in human health — for both researchers and participants. Alethios is an AI-powered decentralized research platform enabling rigorous, affordable virtual studies across life sciences, biotech, longevity, and consumer health, using real-world data from wearables, sensors, and at-home biomarker kits. The Alethiad Participant Community connects researchers with thousands of engaged citizen scientists, enabling faster enrollment, high retention, and participants who are partners in the research process — not just subjects.
Her work spans digital biomarkers, decentralized clinical research, and long COVID, with peer-reviewed publications in Frontiers in Neurology and Karger Digital Biomarkers, a First Opinion piece in STAT News, and speaking engagements ranging from CNS Summit to SupplySide Global. She holds degrees from Harvard and Oxford, where she studied political theory — a foundation that shaped her belief that rigorous research should be accessible to all.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Michael Goldman, SFSU
PMWC Award Ceremony
• David Sinclair, Harvard
• Steve Horvath, Altos Labs
• Nir Barzilai, Albert Einstein College of Medicine
AI-Driven Biomarkers to Quantify Aging
• Chair: Alex Zhavoronkov, Insilico Medicine
• Mahdi Moqri, Harvard
• Steve Horvath, Altos Labs
Epigenetic Aging Signatures in Large Human Cohorts
• Varun Dwaraka, TruDiagnostic
AI Systems for Personalized Longevity: How Biomarkers Translate into Actionable Interventions
• Chair: Nathan Price, Buck Institute
• Sherry Zhang, Buck Institute
• Ranjan Sinha, Digbi Health
Epigenetic Rejuvenation & Delivery for Clinical Translation
• Chair: Ryan (Yuancheng) Lu, Whitehead Institute/MIT
• David Sinclair, Harvard
Clinical Trial Design & Functional Endpoints for Healthspan
• Nir Barzilai, Albert Einstein College of Medicine
• Martin Jensen, Gordian Biotechnology
From Genome to an AI-Drive Longevity Platform
• Wei-Wu He, Human Longevity
• Hussain Ahamed, Ultrahuman
Precision Aging & Longevity Focused on Limited Lifespan Evidence, Vanishing Blue Zones, and Payer ROI
• S. Jay Olshansky, University of Illinois
• Michael Gurven, UC Santa Barbara
